With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...

The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, ...

Lilly’s latest investment comes on the heels of three earlier rounds of manufacturing investment at the LEAP Research and ...

Much of the company’s increase in value has come from intense excitement over its weight loss and diabetes drugs. Specifically, Zepbound and Mounjaro have experienced rapid sales growth. The former ...

New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold ...

A pharmacist warns that off-brand Ozempic, Zepbound, and other weight loss products carry undisclosed risks for consumers.

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

FDA halts actions on makers of compounded drugs as it reviews decision to remove Eli Lilly's (LLY) weight loss drug ...

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Rival manufacturers fight for the right to sell weight loss drugsThere’s a new fight brewing between ...

The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...